Management of Hot Flashes in Postmenopausal Women

First-Line Pharmacologic Options

The National Comprehensive Cancer Network recommends selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) as the most effective first-line nonhormonal treatments for hot flashes in postmenopausal women, with venlafaxine (SNRI) showing 37-61% reduction in hot flash symptoms 1, 2
Venlafaxine (75 mg/day) is particularly effective, reducing hot flash severity by up to 61% and is preferred by patients over gabapentin 1
Paroxetine (7.5 mg daily) effectively reduces frequency and severity of vasomotor symptoms and nighttime awakenings 3
Doses required for hot flash relief are typically lower than those used for depression, with faster response time 1
Common side effects of SNRIs and SSRIs include dry mouth, decreased appetite, fatigue, nausea, constipation, and possible sexual dysfunction 1
The American College of Obstetricians and Gynecologists and other guideline societies suggest that pure SSRIs, especially paroxetine, should be avoided in women taking tamoxifen due to CYP2D6 inhibition that may reduce tamoxifen efficacy 3

Gabapentin (900 mg/day) has been shown to decrease hot flash severity score by 46% at 8 weeks compared to 15% with placebo 1, 3
Clonidine can reduce hot flash frequency and severity in postmenopausal women, although it is less well tolerated than venlafaxine 1

In head-to-head studies, venlafaxine and gabapentin showed similar reductions in hot flash severity, but 68% of participants preferred venlafaxine over gabapentin (32%) 1, 4
Acupuncture has been found to be equivalent to or better than venlafaxine or gabapentin in several comparative studies 1, 5
Weight loss of ≥10% of body weight may help eliminate hot flash symptoms, and smoking cessation can improve frequency and severity of hot flashes 7, 8
Cognitive behavioral therapy (CBT) can reduce the perceived burden of hot flashes, and yoga may improve quality of life associated with menopause, including vasomotor symptoms 5, 8

The National Comprehensive Cancer Network suggests starting with an SNRI (venlafaxine 75 mg/day) or SSRI (except paroxetine if on tamoxifen), and if ineffective or poorly tolerated, switching to gabapentin 900 mg/day 1, 3
For patients who prefer non-drug approaches, acupuncture is recommended, which has comparable efficacy to medications 5
Lifestyle modifications, such as weight loss if overweight, smoking cessation, and limiting alcohol, should be implemented alongside pharmacologic treatment 8